Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Carisma Therapeutics Inc CARM

Healthcare Biotechnology
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the... see more

Recent & Breaking News (NDAQ:CARM)

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors

PR Newswire June 28, 2023

Carisma Therapeutics to be Added to Russell 2000®, Russell 3000® and Russell Microcap® Indexes

PR Newswire June 26, 2023

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in June 2023

PR Newswire May 30, 2023

Carisma Therapeutics to Present at the JMP Securities Life Sciences Conference

PR Newswire May 8, 2023

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in May 2023

PR Newswire May 5, 2023

Carisma Therapeutics to Present at Upcoming Healthcare Industry and Investor Conferences in April 2023

PR Newswire April 6, 2023

Sesen Bio Stockholders Approve Merger with Carisma Therapeutics

Business Wire March 2, 2023

Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results

Business Wire February 28, 2023

SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing Investigations

PR Newswire February 22, 2023

Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With Carisma

Business Wire February 21, 2023

Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote "FOR" All Proposals at March 2 Special Meeting

Business Wire February 16, 2023

Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger

Business Wire February 16, 2023

SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and APEN Shareholders About Its Ongoing Investigations

PR Newswire February 15, 2023

BML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics

Business Wire February 15, 2023

Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger

Business Wire February 14, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SESN, LMST, SAL

PR Newswire February 9, 2023

SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and APEN Shareholders About Its Ongoing Investigations

PR Newswire February 8, 2023

Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger

Business Wire February 2, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANGN, SAFE, SESN, LMST

PR Newswire February 2, 2023

SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and APEN Shareholders About Its Ongoing Investigations

PR Newswire February 1, 2023